摘要
吡嘧司特钾是一种特异性Ⅰ型变态反应抑制剂,临床前研究表明其能稳定肥大细胞膜,抑制细胞外Ca2+内流和细胞内Ca2+的释放,抑制磷酸二酯酶活性,升高细胞内环磷酸腺苷(cAMP)水平,可剂量依赖性地抑制抗原-抗体反应引起组胺、白三烯类物质、前列腺素D3、血栓素B2等的释放。临床研究显示吡嘧司特钾是变异性哮喘、过敏性鼻炎、过敏性结膜炎和特异性皮炎的防治药物,不良反应较轻。文中对该药的理化性质、作用机制、临床前研究、药动学和药效学、临床研究及药物不良反应进行了综述。
Pemirolast potassium is an inhibitor of type Ⅰ allergy.Preclinical studies indicate that it can stabilize the cell membrane of mast cells,inhibit the inflow and release of Ca2＋,inhibit the activation of phosphodiesterase and increase the intracellular cAMP levels.It also dose-dependently suppresses the release of allergic mediators induced by the antigen-antibody reaction,such as histamine,leukotrienes,prostaglandin D3,thromboxane B2 and so on.Clinical studies suggest that pemirolast potassium can prevent and cure variation asthma, anaphylactic rhinitis, anaphylactic conjunctivitis and atopic dermatitis with little untoward reactions. This article provides an overview of the physicochemical properties, action mechanisms, preclinical study, pharmacokinetics and pharmacodynamics,clinical study and the untoward reactions of pemirolast potassium.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2009年第22期2099-2101,共3页
Chinese Journal of New Drugs
关键词
吡嘧司特钾
变态反应抑制剂
过敏性疾病
pemirolast potassium
inhibitor of allergy
anaphylactic disease
